Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH May Play Larger Role in Treating Nervous System Disorders and Diseases
LXRP files for patent with the USPTO for DehydraTECH’s innovative treatment options for diseases and disorders including Alzheimer’s, Huntington’s and Parkinson’s Company hopes to leverage this future possible patent to commercialize its development or out-licensing of future new products that treat central nervous system diseases DehydraTECH platform, being lab tested for drug delivery, effectively transported nicotine across the blood brain barrier, a barrier that protects the brain and makes traditional treatment difficult Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has already received some eight patents granted and nearly 50 pending worldwide, and the company has…